Rating Change
Wells Fargo analysts upgraded Q32 Bio Inc. (NASDAQ:QTTB) from Equal-Weight to Overweight on July 13, 2026.
upgradeNASDAQ:QTTB
Q32 Bio Inc. (QTTB) Upgraded to Overweight at Wells Fargo
Rating Change Wells Fargo analysts upgraded Q32 Bio Inc. (NASDAQ:QTTB) from Equal-Weight to Overweight on July 13, 2026. Market Context Q32 Bio Inc.
Market Context
Q32 Bio Inc. operates in the Healthcare sector. The stock currently trades at $21.38 with a market capitalization of $39.2M.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Wells Fargo's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Q32 Bio Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | Oppenheimer | Outperform | N/A |
| Jul 13, 2026 | Wells Fargo | Overweight | N/A |
| May 22, 2026 | Mizuho | Outperform | N/A |
| May 18, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 05, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View QTTB Stock Page
Frequently Asked Questions
What does a Overweight rating mean for QTTB?
A Overweight rating from Wells Fargo reflects the analyst's outlook on Q32 Bio Inc. (NASDAQ:QTTB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the QTTB forecast page.